Upper body fat predicts metabolic syndrome similarly in men and women

Scott M Grundy, Corbin Williams, Gloria L Vega

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The metabolic syndrome is a constellation of risk factors including dyslipidemia, dysglycemia, hypertension, a pro-inflammatory state, and a prothrombotic state. All of these factors are accentuated by obesity. However, obesity can be defined by body mass index (BMI), percent body fat, or by body fat distribution. The latter consists of upper body fat (subcutaneous and visceral fat) and lower body fat (gluteofemoral fat). Waist circumference is a common surrogate marker for upper body fat. Methods: Data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2006 was examined for associations of metabolic risk factors with percent body fat, waist circumference, and BMI. Results: Associations between absolute measures of waist circumference and risk factors were similiar for men and women. The similarities of associations between waist circumference and risk factors suggests that greater visceral fat in men does not accentuate the influence of upper body fat on risk factors. Conclusions: Different waist concumference values should not be used to define abdominal obesity in men and women.

Original languageEnglish (US)
JournalEuropean Journal of Clinical Investigation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Adipose Tissue
Fats
Waist Circumference
Intra-Abdominal Fat
Body Mass Index
Obesity
Body Fat Distribution
Abdominal Obesity
Nutrition Surveys
Subcutaneous Fat
Dyslipidemias
Biomarkers
Hypertension
Nutrition
Health

Keywords

  • Body fat
  • Metabolic syndrome
  • Obesity
  • Risk factors

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

@article{f278facf9cd64b83ae46ce1ed77781be,
title = "Upper body fat predicts metabolic syndrome similarly in men and women",
abstract = "Background: The metabolic syndrome is a constellation of risk factors including dyslipidemia, dysglycemia, hypertension, a pro-inflammatory state, and a prothrombotic state. All of these factors are accentuated by obesity. However, obesity can be defined by body mass index (BMI), percent body fat, or by body fat distribution. The latter consists of upper body fat (subcutaneous and visceral fat) and lower body fat (gluteofemoral fat). Waist circumference is a common surrogate marker for upper body fat. Methods: Data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2006 was examined for associations of metabolic risk factors with percent body fat, waist circumference, and BMI. Results: Associations between absolute measures of waist circumference and risk factors were similiar for men and women. The similarities of associations between waist circumference and risk factors suggests that greater visceral fat in men does not accentuate the influence of upper body fat on risk factors. Conclusions: Different waist concumference values should not be used to define abdominal obesity in men and women.",
keywords = "Body fat, Metabolic syndrome, Obesity, Risk factors",
author = "Grundy, {Scott M} and Corbin Williams and Vega, {Gloria L}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/eci.12941",
language = "English (US)",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Upper body fat predicts metabolic syndrome similarly in men and women

AU - Grundy, Scott M

AU - Williams, Corbin

AU - Vega, Gloria L

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The metabolic syndrome is a constellation of risk factors including dyslipidemia, dysglycemia, hypertension, a pro-inflammatory state, and a prothrombotic state. All of these factors are accentuated by obesity. However, obesity can be defined by body mass index (BMI), percent body fat, or by body fat distribution. The latter consists of upper body fat (subcutaneous and visceral fat) and lower body fat (gluteofemoral fat). Waist circumference is a common surrogate marker for upper body fat. Methods: Data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2006 was examined for associations of metabolic risk factors with percent body fat, waist circumference, and BMI. Results: Associations between absolute measures of waist circumference and risk factors were similiar for men and women. The similarities of associations between waist circumference and risk factors suggests that greater visceral fat in men does not accentuate the influence of upper body fat on risk factors. Conclusions: Different waist concumference values should not be used to define abdominal obesity in men and women.

AB - Background: The metabolic syndrome is a constellation of risk factors including dyslipidemia, dysglycemia, hypertension, a pro-inflammatory state, and a prothrombotic state. All of these factors are accentuated by obesity. However, obesity can be defined by body mass index (BMI), percent body fat, or by body fat distribution. The latter consists of upper body fat (subcutaneous and visceral fat) and lower body fat (gluteofemoral fat). Waist circumference is a common surrogate marker for upper body fat. Methods: Data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2006 was examined for associations of metabolic risk factors with percent body fat, waist circumference, and BMI. Results: Associations between absolute measures of waist circumference and risk factors were similiar for men and women. The similarities of associations between waist circumference and risk factors suggests that greater visceral fat in men does not accentuate the influence of upper body fat on risk factors. Conclusions: Different waist concumference values should not be used to define abdominal obesity in men and women.

KW - Body fat

KW - Metabolic syndrome

KW - Obesity

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85047612839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047612839&partnerID=8YFLogxK

U2 - 10.1111/eci.12941

DO - 10.1111/eci.12941

M3 - Article

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

ER -